Purchase premium 44-dmar

44-dmar, also known as 4,4′-Dimethylaminorex or “Serotoni” on the streets, is a psychostimulant and entactogen designer drug associated with aminorex, 4-methylaminorex, and pemoline. It was initially identified in the Netherlands in December 2012 and has been marketed as a designer drug across Europe since mid-2013.

The use of 44-dmar has been linked to at least 31 deaths in Hungary, Poland, and the UK by February 2014, often when combined with other substances. In Northern Ireland, 19 deaths related to 44-dmar were reported within a similar timeframe.

Functioning as a potent serotonin-norepinephrine-dopamine releasing agent (SNDRA), 44-dmar exhibits EC50 values for serotonin, norepinephrine, and dopamine release of 18.5 nM, 26.9 nM, and 8.6 nM, respectively.

Chemically, 44-dmar, with the IUPAC name 4-methyl-5-(4-methylphenyl)- 4,5-dihydrooxazol-2-amine, is a derivative of both aminorex and 4-methylaminorex. It is classified in Schedule IV of the 1971 United Nations Convention on Psychotropic Substances.

Pharmacologically, there are no human studies available, but recent studies in male Sprague-Dawley rat synaptosomes have examined the monoamine release induced by (+/−)- cis-4,4′-DMAR compared to d-amphetamine, aminorex, and (+/−)- cis-4-methylaminorex. The findings indicate that (+/−)- cis-44-dmar is a robust dopamine, noradrenaline, and serotonin releaser.

Toxicologically, no pre-clinical or clinical studies have evaluated the toxic effects of 44-dmar in humans. However, as of October 2013, 44-dmar has been implicated in 31 deaths and one serious intoxication reported to the EMCDDA through the early warning system.

There is no approved clinical use for 44-dmar, and it is strictly intended for research and forensic purposes. However, the (4S,5S)- trans-4,4′-DMAR enantiomer has been used in some patients in connection with the preparation of anti-inflammatory drugs based on phospholipase A2 inhibitors.

Legally, there is no immunoassay field test available for detecting 44-dmar in biological samples, and its cross-reactivity with other common drugs of abuse is unknown. The UK Home Office moved to classify 44-dmar as a Class A drug on March 11, 2015, following guidance from the Advisory Council on the Misuse of Drugs.